Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04780568 · ClinicalTrials.gov registry record · Phase 1

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

A Phase 1 study of Stage IV Lung Cancer AJCC v8 and Metastatic Lung Non-Small Cell Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT04780568 is a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Metastatic Lung Non-Small Cell Carcinoma that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 24 participants, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04780568, a Phase 1 study of Stage IV Lung Cancer AJCC v8 and Metastatic Lung Non-Small Cell Carcinoma, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions Studied

Stage IV Lung Cancer AJCC v8 Metastatic Lung Non-Small Cell Carcinoma Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8

Interventions

  • PROCEDURE Computed Tomography
  • DRUG Osimertinib
  • PROCEDURE Echocardiography Test
  • DRUG Tegavivint
  • PROCEDURE Multigated Acquisition Scan

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2022-01-18
Est. Completion 2029-07-31
Phase Phase 1

Sponsor

Ohio State University Comprehensive Cancer Center

341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04780568

The ClinicalTrials.gov registry entry for NCT04780568 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 81 other Stage IV Lung Cancer AJCC v8 trials with a reported enrollment target (76% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Stage IV Lung Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.

NCT04780568 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04780568 about?

NCT04780568 is a clinical study titled "Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer". This phase Ib trial is to find out the best dose, possible benefits and/or side effects of osimertinib and tegavivint as first-line therapy in treating patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (metastatic). Osimertinib and tegavivint may stop t...

What is the current status of trial NCT04780568?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2022-01-18. Estimated completion is 2029-07-31.

What conditions does trial NCT04780568 study?

This clinical trial studies the following conditions: Stage IV Lung Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8.

What interventions are being tested in trial NCT04780568?

The interventions under investigation include: Computed Tomography (PROCEDURE), Osimertinib (DRUG), Echocardiography Test (PROCEDURE), Tegavivint (DRUG), Multigated Acquisition Scan (PROCEDURE).

Who is sponsoring clinical trial NCT04780568?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04780568 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IV Lung Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Stage IV Lung Cancer AJCC v8

All registered trials for this condition

Metastatic Lung Non-Small Cell Carcinoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.